KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023)

BeOne Medicines (ONC) has disclosed Long-Term Deferred Tax for 8 consecutive years, with $2.0 billion as the latest value for Q4 2023.

  • On a quarterly basis, Long-Term Deferred Tax fell 2.38% to $2.0 billion in Q4 2023 year-over-year; TTM through Dec 2023 was $2.0 billion, a 2.38% decrease, with the full-year FY2023 number at $2.0 billion, down 2.38% from a year prior.
  • Long-Term Deferred Tax was $2.0 billion for Q4 2023 at BeOne Medicines, down from $2.1 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $2.1 billion in Q4 2022 to a low of $30.5 million in Q1 2019.
  • A 5-year average of $314.9 million and a median of $72.1 million in 2020 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 1783.48% in 2022, then fell 2.38% in 2023.
  • BeOne Medicines' Long-Term Deferred Tax stood at $37.9 million in 2019, then surged by 74.07% to $66.0 million in 2020, then soared by 67.41% to $110.4 million in 2021, then surged by 1783.48% to $2.1 billion in 2022, then fell by 2.38% to $2.0 billion in 2023.
  • Per Business Quant, the three most recent readings for ONC's Long-Term Deferred Tax are $2.0 billion (Q4 2023), $2.1 billion (Q4 2022), and $103.4 million (Q2 2022).